Literature DB >> 3020820

Development of an attenuated strain of chikungunya virus for use in vaccine production.

N H Levitt, H H Ramsburg, S E Hasty, P M Repik, F E Cole, H W Lupton.   

Abstract

An attenuated chikungunya (CHIK) virus clone was developed for production of a live vaccine for human use. CHIK strain 15561 was subjected to 18 plaque-to-plaque passages in MRC-5 cultures before CHIK 181/clone 25 was selected as vaccine seed based on homogeneous small plaque size, suckling mouse avirulence, reduced monkey viraemia and genetic stability. Oligonucleotide mapping demonstrated differences between parent and clone. Vaccine (pilot-lot production) elicited neutralizing antibody and protected mice and rhesus monkeys against challenge. After challenge, viraemias were absent in vaccinated monkeys. Vaccine was then produced and tested in accordance with governmental regulatory requirements of human use.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020820     DOI: 10.1016/0264-410x(86)90003-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  98 in total

1.  Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus.

Authors:  Justin R Darwin; Joan L Kenney; Scott C Weaver
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.

Authors:  Christina L Gardner; Crystal W Burke; Stephen T Higgs; William B Klimstra; Kate D Ryman
Journal:  Virology       Date:  2012-02-01       Impact factor: 3.616

3.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.

Authors:  Karine Labadie; Thibaut Larcher; Christophe Joubert; Abdelkrim Mannioui; Benoit Delache; Patricia Brochard; Lydie Guigand; Laurence Dubreil; Pierre Lebon; Bernard Verrier; Xavier de Lamballerie; Andreas Suhrbier; Yan Cherel; Roger Le Grand; Pierre Roques
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

4.  Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Authors:  Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

5.  The synergistic effect of nsP2-L618, nsP3-R117, and E2-K187 on the large plaque phenotype of chikungunya virus.

Authors:  Benjawan Thoka; Thitigun Jaimipak; Supachoke Onnome; Sutee Yoksan; Sukathida Ubol; Rojjanaporn Pulmanausahakul
Journal:  Virus Genes       Date:  2017-11-28       Impact factor: 2.332

6.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

7.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

8.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

9.  Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.

Authors:  Ivan Akhrymuk; Tetyana Lukash; Ilya Frolov; Elena I Frolova
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

10.  Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic.

Authors:  Alladi Mohan; D H N Kiran; I Chiranjeevi Manohar; D Prabath Kumar
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.